title: Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
authors.affiliation: Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre , Toronto , Canada.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Shanavas
authors.forename: Hans A
authors.initials: HA
authors.lastname: Messner
authors.forename: Suzanne
authors.initials: S
authors.lastname: Kamel-Reid
authors.forename: Eshetu G
authors.initials: EG
authors.lastname: Atenafu
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: John
authors.initials: J
authors.lastname: Kuruvilla
authors.forename: Dennis Dong Hwan
authors.initials: DD
authors.lastname: Kim
authors.forename: Jieun
authors.initials: J
authors.lastname: Uhm
authors.forename: Anna
authors.initials: A
authors.lastname: Lambie
authors.forename: Laura
authors.initials: L
authors.lastname: Ellis
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Lipton
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D012008:Recurrence; D017741:Survivors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016044:Fusion Proteins, bcr-abl